Posts Archive

Multiple Myeloma Research Consortium phase 2 study Dara-KRd NCT03500445: Phase 2: Daratumumab, Carfilzomib, Lenalidomide and Low Dose...

DREAMM 2 Relapsed & Refractory Multiple Myeloma A Study to Investigate the Efficacy and Safety of Two Doses of GSK2857916 in Participants...

NCT03589222: Phase 2: SELIBORDARA: Selinexor, Bortezomib and Daratumumab in Multiple Myeloma NCT03589222: Phase 2: SELIBORDARA:...

MANHATTAN TRIAL NCT03290950: Phase 2 - A Study of Daratumumab in Patients With Newly Diagnosed Multiple Myeloma Dara-KRd A Study of...

ASCENT TRIAL Dara-KRd Aggressive Smoldering Curative Approach Evaluating Novel Therapies and Transplant (ASCENT) This study evaluates the...

NCT03236428: Phase 2: Phase II Study of the CD38 Antibody Daratumumab in Patients With High-Risk MGUS and Low-Risk Smoldering Multiple...

Phase II HOVON 143 Study Trial Update 63rd ASH Annual Meeting 80 Ixazomib, Daratumumab and Low Dose Dexamethasone in Intermediate-Fit...

Multiple Myeloma Research Consortium NCT03346135: Phase 2: Daratumumab After Stem Cell Transplant in Treating Patients With Multiple...

GMMG - The German Speaking Myeloma Multicenter Group GMMG-CONCEPT trial Isa-KRd NCT03104842: Phase 2 - Evaluation iNduction,...

A Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Participants With Relapsed...

NCT03012880: Phase 2 - Ixazomib Citrate, Lenalidomide, Dexamethasone, and Daratumumab in Treating Patients With Newly Diagnosed Multiple...

A Study Of Daratumumab, Low-Dose Oral Dexamethasone and Cyclophosphamide With Or Without Pomalidomide (DCDP) This is a randomized phase...

Multiple Myeloma Research Consortium NCT03030261: Phase 2: Elotuzumab, Pomalidomide, & Dexamethasone (Elo-Pom-Dex) With Second Autologous...

MUKnineb Study OPTIMUM To determine whether a combination of four novel agents bortezomib(Velcade), lenalidomide (Revlimid), Daratumumab...

KarMMa bb2121 NCT03361748: Phase 2 - Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma...

NCT03336073: Phase 2: GEM-KyCyDex - Carfilzomib, Cyclophosphamide, Dexamethasone in Multiple Myeloma This is a multicenter, open label,...

MASTER TRIAL Monoclonal Antibody-Based Sequential Therapy for Deep Remission in Multiple Myeloma (MASTER) Dara-KRd Monoclonal...

The GRIFFIN trial Study Comparing Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) Versus Lenalidomide, Bortezomib, and...

Isatuximab in Treating Patients With High Risk Smoldering Plasma Cell Myeloma This phase II trial studies how well isatuximab works in...